Effectiveness of osimertinib in patients with lung adenocarcinoma in clinical practice - the Expanded Drug Access Program in Poland.
Magdalena Knetki-WroblewskaDariusz M KowalskiGrzegorz CzyżewiczMaciej BrylAnna WronaRafał DziadziuszkoRobert KieszkoJanusz MilanowskiDaria ŚwiniuchRodryg RamlauMaciej KrzakowskiPublished in: Advances in respiratory medicine (2021)
These results confirm the value of osimertinib in patients with previously treated EGFR T790M-mutant NSCLC. Clinical benefit was evident in patients with cerebral metastases and moderate performance status.
Keyphrases
- small cell lung cancer
- epidermal growth factor receptor
- advanced non small cell lung cancer
- clinical practice
- brain metastases
- randomized controlled trial
- systematic review
- quality improvement
- tyrosine kinase
- subarachnoid hemorrhage
- high intensity
- adverse drug
- emergency department
- cerebral ischemia
- brain injury
- drug induced
- blood brain barrier
- electronic health record